Indofarma Targets Revenue Of IDR 1.86 Trillion In 2023

Photo: Didi Kurniawan/VOI

JAKARTA - PT Indofarma Tbk (INAF) projects revenue of IDR 1.86 trillion in 2023. This target is equivalent to growth of 63.36 percent from last year's revenue realization.

"The company projects revenue of IDR 1.86 trillion, with a growth of 63.36 percent of the realization of revenue in 2022. With a gross profit of IDR 406 billion or a margin of 22 percent, it is hoped that the profit for the year earned in 2023 will be IDR 5.1 billion," said PT Indofarma Tbk President Director Agus Heru Darjono in Jakarta, Wednesday, May 31.

Agus explained, in early 2023 Indofarma initiated a change in strategy by changing the approach from only Business to Consumer (B to C) to Business (B to B) with a pattern of cooperation or partnership in production and marketing.

"In addition, the Company focuses on product groups that are in accordance with the market needs and capabilities of the Company, optimizing the export market and utilizing the Company's factory facilities for the production of Natural Extract which has been certified as CPOTB, Halal and HACCP," he said.

As of May 2023, the strategic shift has been realized through the Signing of Distribution Cooperation with PT Bintang Kencana Artha (BAK), Production and Marketing Cooperation Agreement with PT Quantum Laboratories International, Toll Manufacturing Cooperation Agreement with PT Rama Emerald Multi Sukses, and collaboration with SMESCO Indonesia in increasing the marketing of cooperative products and technology-based small and medium-sized businesses.

This was conveyed by Agus in the holding of the Annual General Meeting of Shareholders (AGMS) which was also attended by the Director of Finance, Risk Management and HR of Indofarma Ariesta Krisnawan, Director of Production and Supply Chain Indofarma Jejen Nugraha and Director of Sales and Marketing Kamelia Faisal.